Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Nanoparticles target brain tumors

BioPhotonics
Dec 2006
Nanoparticles packed with high concentrations of a proven cancer-killing drug may provide a safer and more effective way to target brain tumors, researchers at the University of Michigan Comprehensive Cancer Center have found.

Administration of the light-sensitive drug Photofrin into the system to attack cancer cells usually is accompanied by a number of potentially serious side effects, including sensitivity to light that can last up to six weeks. The powerful PDT drug also can damage healthy tissue en route to the diseased site.

To overcome these problems, investigators led by Brian D. Ross and Raoul Kopelman incorporated the photosensitizer, along with iron oxide, into nanoparticles that served as couriers, directly delivering the dose to the cancerous tumor (see figure). A laser then activated the drug. The iron oxide served as a contrast agent for an enhanced MRI.

The nanoparticle delivery system was tested in vivo on rats with brain tumors, and the researchers found less exposure to surrounding healthy tissue and increased concentrations of the drug in tumoral areas. Rats that received the photosensitizer by a traditional systemic injection survived 13 days, while those treated with the nanoparticle delivery system survived an average of 33 days. Forty percent of the rats were disease-free after six months. The results appeared in the Nov. 15 issue of Clinical Cancer Research.

The research suggests that the nanoparticle method could carry higher doses of virtually any drug harmful to healthy tissue, delivering a more powerful payload directly to the disease. If nanoparticle delivery is found to be safe in humans, it could result in drugs with particularly harmful side effects being reintroduced for use.

Further research is needed before the method can be tested in clinical trials.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!